{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:08:20Z","timestamp":1793984900394,"version":"4.8.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>In Crohn\u2019s disease (CD), symptomatic and endoscopic assessments often show poor correlation. Bile acid malabsorption is a common comorbidity in these patients and often results in bile acid diarrhea (BAD). This post-hoc clinical trial analysis evaluated BAD presence and its association with symptoms and disease activity in patients with active CD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The bile acid precursor, serum 7a-hydroxy-4cholestern-3-one (C4), was analyzed before and after adalimumab therapy in patients with moderate to severe CD. Patients were stratified by C4 concentration to evaluate the association of BAD with symptomatic and endoscopic disease activity.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Elevated baseline serum C4 (C4\u2005\u2265\u200548.3\u00a0ng\/mL) was present in 37.1% of patients with active CD, was most frequently associated with isolated ileal disease, and persistent in many patients after treatment. Compared to C4 concentrations maintained within the normal range, persistently elevated\u00a0C4\u2005\u2265\u200548.3\u00a0ng\/mL was associated with reduced stool frequency\/abdominal pain score (SF\/APS) clinical remission (23.9% vs 55.9%, P\u2005&amp;lt;\u2005.001), and SF remission (28.3% vs 67.7%, P\u2005&amp;lt;\u2005.001), but not endoscopic remission (43.5% vs 53.1%). In patients with endoscopic remission, those with C4\u2005\u2265\u200548.3\u00a0ng\/mL demonstrated reduced SF\/APS clinical remission (28.0% vs 51.0%) and SF remission (36.0% vs 67.7%), but similar AP remission (72.0% vs 70.8%) compared to those with normal C4 concentration.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In active CD, BAD was prevalent, particularly in isolated ileal disease, and associated with persistent diarrhea, but not endoscopic remission after treatment. These findings shed light on the discordance between symptomatic and endoscopic assessments observed in CD clinical trials and the challenges in treating isolated ileal disease. ClinicalTrials.gov NCT02065570<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf053","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T14:24:11Z","timestamp":1744208651000},"source":"Crossref","is-referenced-by-count":2,"title":["Association of bile acid diarrhea with symptoms and disease activity in Crohn\u2019s disease: post-hoc clinical trial analysis of serum 7a-hydroxy-4cholestern-3-one, C4, in patients with active Crohn\u2019s disease"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7421-9764","authenticated-orcid":false,"given":"Robert","family":"Battat","sequence":"first","affiliation":[{"name":"Center for Clinical Excellence and Translational Research in Inflammatory Bowel Diseases, University of Montreal Hospital Center (CHUM) , Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8007-3802","authenticated-orcid":false,"given":"Soumya","family":"Kandi","sequence":"additional","affiliation":[{"name":"Quantitative, Translational and ADME Sciences, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P","family":"Lacerda","sequence":"additional","affiliation":[{"name":"Clinical Development, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil","family":"Levine","sequence":"additional","affiliation":[{"name":"Immunology and Inflammation, Sanofi Inc , Cambridge, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel","family":"Neimark","sequence":"additional","affiliation":[{"name":"Clinical Development, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G","family":"Feagan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Western Ontario\/Alimentiv Inc , London, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"The University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin C","family":"Ji","sequence":"additional","affiliation":[{"name":"Quantitative, Translational and ADME Sciences, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[{"name":"Discovery and Exploratory Statistics, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Blink","family":"Polakow","sequence":"additional","affiliation":[{"name":"Precision Medicine, Immunology, AbbVie Inc , North Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2025060311001535200_CIT0001","first-page":"304","article-title":"Correlation of stool frequency and abdominal pain measures with simple endoscopic score for Crohn\u2019s disease","volume":"26","author":"Lewis","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311001535200_CIT0002","doi-asserted-by":"crossref","first-page":"otad017","DOI":"10.1093\/crocol\/otad017","article-title":"The impact of confounders on symptom-endoscopic discordances in Crohn\u2019s disease","volume":"5","author":"Rajan","year":"2023","journal-title":"Crohns Colitis 360."},{"key":"2025060311001535200_CIT0003","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S2468-1253(20)30300-9","article-title":"Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis","volume":"5","author":"Fairbrass","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025060311001535200_CIT0004","first-page":"407","article-title":"Intestinal bile acid transport: biology, physiology, and pathophysiology","volume":"32","author":"Shneider","year":"2001","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2025060311001535200_CIT0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hep.20295","article-title":"Bile acid-induced negative feedback regulation of the human ileal bile acid transporter","volume":"40","author":"Neimark","year":"2004","journal-title":"Hepatology."},{"key":"2025060311001535200_CIT0006","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/gut.53.1.78","article-title":"Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor","volume":"53","author":"Jung","year":"2004","journal-title":"Gut."},{"key":"2025060311001535200_CIT0007","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1113\/jphysiol.2014.270892","article-title":"Physiological underpinnings of irritable bowel syndrome: neurohormonal mechanisms","volume":"592","author":"Camilleri","year":"2014","journal-title":"J Physiol."},{"key":"2025060311001535200_CIT0008","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.cgh.2018.11.012","article-title":"Serum concentrations of 7\u03b1-hydroxy-4-cholesten-3-one are associated with bile acid diarrhea in patients with Crohn\u2019s disease","volume":"17","author":"Battat","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311001535200_CIT0009","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/ecco-jcc\/jjac173","article-title":"Increased primary bile acids with ileocolonic resection impact ileal inflammation and gut microbiota in inflammatory bowel disease","volume":"17","author":"Battat","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025060311001535200_CIT0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5009\/gnl14397","article-title":"Bile acid diarrhea: prevalence, pathogenesis, and therapy","volume":"9","author":"Camilleri","year":"2015","journal-title":"Gut Liver"},{"key":"2025060311001535200_CIT0011","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ibd.21502","article-title":"Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers","volume":"17","author":"Lenicek","year":"2011","journal-title":"Inflamm Bowel Dis."},{"key":"2025060311001535200_CIT0012","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/apt.13570","article-title":"Review article: bile acid diarrhoea\u2014pathogenesis, diagnosis and management","volume":"43","author":"Mottacki","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311001535200_CIT0013","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3389\/fphys.2020.00564","article-title":"IBD and bile acid absorption: focus on pre-clinical and clinical observations","volume":"11","author":"Fitzpatrick","year":"2020","journal-title":"Front Physiol."},{"key":"2025060311001535200_CIT0014","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.cgh.2013.04.029","article-title":"Methods for diagnosis of bile acid malabsorption in clinical practice","volume":"11","author":"Vijayvargiya","year":"2013","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311001535200_CIT0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jhep.2012.08.002","article-title":"Bile acid transporters and regulatory nuclear receptors in the liver and beyond","volume":"58","author":"Halilbasic","year":"2013","journal-title":"J Hepatol."},{"key":"2025060311001535200_CIT0016","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7861\/clinmedicine.10-2-124","article-title":"Bile acid malabsoption: a forgotten diagnosis","volume":"10","author":"Khalid","year":"2010","journal-title":"Clin Med (Lond)"},{"key":"2025060311001535200_CIT0017","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/978-1-4614-0887-1_11","article-title":"Physiology of FGF15\/19","volume":"728","author":"Jones","year":"2012","journal-title":"Adv Exp Med Biol."},{"key":"2025060311001535200_CIT0018","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/apt.12466","article-title":"Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention","volume":"38","author":"Pattni","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311001535200_CIT0019","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1155\/2011\/701287","article-title":"An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea","volume":"25","author":"Brydon","year":"2011","journal-title":"Can J Gastroenterol."},{"key":"2025060311001535200_CIT0020","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00042737-200604000-00013","article-title":"Normal or increased bile acid uptake in isolated mucosa from patients with bile acid malabsorption","volume":"18","author":"Bajor","year":"2006","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025060311001535200_CIT0021","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1053\/j.gastro.2020.07.001","article-title":"Combined fasting serum C4 and primary bile acids from a single stool sample to diagnose bile acid diarrhea","volume":"159","author":"Vijayvargiya","year":"2020","journal-title":"Gastroenterology."},{"key":"2025060311001535200_CIT0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/apt.17739","article-title":"Prospective comparison of diagnostic tests for bile acid diarrhoea","volume":"59","author":"Borup","year":"2024","journal-title":"Aliment Pharmacol Ther."},{"key":"2025060311001535200_CIT0023","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2468-1253(22)00401-0","article-title":"Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial","volume":"8","author":"Borup","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025060311001535200_CIT0024","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1053\/j.gastro.2022.01.044","article-title":"Higher vs standard adalimumab induction dosing regimens and two maintenance strategies: randomized SERENE CD trial results","volume":"162","author":"D\u2019Haens","year":"2022","journal-title":"Gastroenterology."},{"key":"2025060311001535200_CIT0025","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.4155\/bio-2016-0219","article-title":"A simple, fast, sensitive and robust LC-MS\/MS bioanalytical assay for evaluating 7\u03b1-hydroxy-4-cholesten-3-one biomarker in a clinical program","volume":"8","author":"Yuan","year":"2016","journal-title":"Bioanalysis"},{"key":"2025060311001535200_CIT0026","doi-asserted-by":"crossref","first-page":"116581","DOI":"10.1016\/j.jpba.2024.116581","article-title":"High throughput bioanalysis of serum 7a-hydroxy-4-cholesten-3-one (C4) using LC-MS\/MS: devising an end-to-end single vial solution for a sample limited application","volume":"255","author":"Kandi","year":"2024","journal-title":"J Pharm Biomed Anal."},{"key":"2025060311001535200_CIT0027","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1007\/s10620-024-08421-w","article-title":"Correlation between serum and fecal biomarkers and patient-reported outcomes in patients with Crohn\u2019s disease and ulcerative colitis","volume":"69","author":"Motwani","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2025060311001535200_CIT0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5009\/gnl13424","article-title":"Usefulness of C-reactive protein as a disease activity marker in Crohn\u2019s disease according to the location of disease","volume":"9","author":"Yang","year":"2015","journal-title":"Gut Liver."},{"key":"2025060311001535200_CIT0029","doi-asserted-by":"crossref","first-page":"17562848241251600","DOI":"10.1177\/17562848241251600","article-title":"Biomarkers in inflammatory bowel disease: a practical guide","volume":"17","author":"Clough","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"2025060311001535200_CIT0030","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/ajg.2009.579","article-title":"The natural history of adult Crohn\u2019s disease in population-based cohorts","volume":"105","author":"Peyrin-Biroulet","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2025060311001535200_CIT0031","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cgh.2011.04.031","article-title":"Certolizumab pegol for active Crohn\u2019s disease: a placebo-controlled, randomized trial","volume":"9","author":"Sandborn","year":"2011","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025060311001535200_CIT0032","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2025060311001535200_CIT0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"2025060311001535200_CIT0034","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ecco-jcc\/jjab133","article-title":"Efficacy and safety of subcutaneous vedolizumab in patients with moderately to severely active Crohn\u2019s disease: results from the VISIBLE 2 randomised trial","volume":"16","author":"Vermeire","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025060311001535200_CIT0035","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3748\/wjg.v27.i24.3609","article-title":"Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis","volume":"27","author":"Yang","year":"2021","journal-title":"World J Gastroenterol."},{"key":"2025060311001535200_CIT0036","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1365-2796.2006.01731.x","article-title":"Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man","volume":"260","author":"Lundasen","year":"2006","journal-title":"J Intern Med."},{"key":"2025060311001535200_CIT0037","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-2362.1999.00475.x","article-title":"Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway","volume":"29","author":"Naoumova","year":"1999","journal-title":"Eur J Clin Invest."},{"key":"2025060311001535200_CIT0038","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0014-5793(91)80382-D","article-title":"Ethanol has an acute effect on bile acid biosynthesis in man","volume":"281","author":"Axelson","year":"1991","journal-title":"FEBS Lett."},{"key":"2025060311001535200_CIT0039","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/MEG.0000000000000476","article-title":"Diagnosis of bile acid diarrhoea by fasting and postprandial measurements of fibroblast growth factor 19","volume":"27","author":"Borup C Syversen","year":"2015","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2025060311001535200_CIT0040","doi-asserted-by":"crossref","first-page":"E241","DOI":"10.1210\/jc.2013-3129","article-title":"Carbohydrate feeding diassociates the postprandial FGF19 response from circulating bile acid levels in humans","volume":"99","author":"Morton","year":"2014","journal-title":"J Clin Endocrinol Metab."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf053\/62897155\/jjaf053.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf053\/62897155\/jjaf053.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf053\/62897155\/jjaf053.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:01:34Z","timestamp":1748962894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf053\/8109177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf053","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,4,9]]},"article-number":"jjaf053"}}